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Objective: The purpose of this review is to present the complex underlying pathophys-
iology that can form the basis of this common condition. Methods: More than 20 years
of clinical experience in endocrinology and plastic surgery and a review of the English-
language literature were used to form the basis of this review. Results: While idiopathic
and physiologic causes are frequent, there are multiple, significant, underlying disor-
ders that can result in gynecomastia, including chronic illness, cancer, medications,
syndromes, and a variety of endocrinopathies. Conclusion: Both history and physical
examination are frequently sufficient to make an appropriate diagnosis. In patients who
do not have a definitive etiology of their gynecomastia, a screening battery of laboratory
tests is sufficient to rule out significant pathophysiology, although these tests may be
difficult to interpret in children and adolescents. An endocrinology consultation is sug-
gested whenever an abnormal screening laboratory test occurs or if there are any other
suggestions of underlying endocrinopathy.
DESCRIPTION
Gynecomastia refers to the condition of breast development in a male. It can occur in boys
and men of all ages and is most common in infancy and adolescence and in middle-aged
to older men. The pathophysiology of gynecomastia is felt to be an imbalance of estrogens
and androgens, with a decreased testosterone-to-estradiol ratio.1 This imbalance can occur
through many mechanisms and directly affects breast tissue.2 Transient gynecomastia is
estimated to occur in 60% to 90% of male infants secondary to high estrogen state during
pregnancy.3,4 Pubertal gynecomastia has a peak prevalence of nearly 65% and occurs at
about 14 years of age.3,5 Older men also develop involutional gynecomastia, with a preva-
lence of 40% to 55%, seen at autopsy.6 Frequently, the etiology of gynecomastia is evident
when a thorough history and physical examination are performed. When the etiology is
not apparent, then a series of laboratory tests should be performed to rule out significant
underlying pathophysiology.
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Table 1. Conditions associated with gynecomastia3,5,6,11
Physiologic
Neonatal
Pubertal
Involutional
Pathologic
Neoplasms
Testicular
Pituitary
Breast tumors
Adrenal
Liver
Human Chorionic Gonadotropin—ectopic production
Lymphoma/leukemia
Endocrinopathies
Hypogonadism
Syndromes: Klinefelter, Kallman’s
Androgen insensitivity
Hermaphroditism
Enzymatic defects of testosterone synthesis
Testicular injury/regression
Hyperthyroidism
High aromatase
Adrenal hyperplasia
Corticotropin deficiency
Chronic Illnesses:
Liver disease
Renal disease
Malnutrition
Cystic fibrosis
AIDS
Ulcerative Colitis
Medications (see Table 3)
PATHOPHYSIOLOGY
Gynecomastia is associated with a host of conditions as well as numerous additional eti-
ologies (Tables 1 and 2). The altered ratio of estrogens to androgens or increased breast
sensitivitytonormalcirculatingestrogenlevelsresultsinductalhyperplasia,elongation,and
branching, along with fibroblast proliferation and increased vascularity.7−10 Males produce
estrogenprimarilyfromconvertingperipheralandrogens,testosteroneandandrostenedione,
to estradiol and estrone via the aromatase enzyme. This occurs mainly in muscle, fat, and
skin. In a male adult, the normal production ratio of androgen to estrogen is 100:1. In the
circulation, the ratio of testosterone to estrogen is 300:1.11
It is sometimes difficult to differentiate between fatty tissue and breast tissue,
especially in overweight individuals (Fig 1). Gynecomastia is clinically defined by the
presenceofarubbery,firmmassextendingconcentricallyfromthenipples.Thissubareolar
disk of glandular tissue has been described as feeling like a corded rope.5 In contrast,
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Table 2. Etiologies of gynecomastia3,11
Idiopathic gynecomastia (no detectable abnormalitiy) 25%
Pubertal gynecomastia 25%
Secondary to medication 10–20%
Cirrhosis or malnutrition 8%
Primary hypogonadism 8%
Testicular tumors 3%
Secondary hypogonadism 2%
Hyperthyroidism 1.5%
Chronic renal disease 1%
Figure 1. Obese patient with fatty breasts and enlarged breast
nodules.
pseudogynecomastia is defined as the proliferation of soft subcutaneous fat that can give
males the appearance of developing breasts. Breast development can be unilateral or
bilateral and asymmetry is often an early stage in the development of gynecomastia (Fig 2).
The histology associated with gynecomastia is related more to the duration than the
cause of the process. When the condition is asymptomatic, it has frequently existed for
monthsoryearspriortopresentation.Chronicchangesincludedilatedductswithperiductal
fibrosis, stromal hyalinization, and increased subareolar fat. Those presenting with pain
and tenderness frequently have breast hypertrophy of more recent onset. In contrast, their
pathologic studies show ductal hyperplasia with inflammation of the periductal tissue and
subareolar fat.6–10
Pubertal gynecomastia refers to the transient condition of breast development occur-
ring in 10- to 16-year-old boys (Fig 3). About 40% of boys develop this condition, which
peaks at 14 years of age at nearly 65% incidence. These statistics are based on clinical
studies detecting breast enlargement as small as 0.5 cm in diameter. About 10% of boys
report gynecomastia in general surveys of sexual development.5 Some investigators have
found brief elevations of plasma estradiol in some affected male adolescents, but sustained
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Figure 2. Asymmetric breast development.
Figure 3. Pubertal gynecomastia.
elevationsofestrogensarenotpresentinpubertalgynecomastia. 1,12 Thepathogenesisofpu-
bertal gynecomastia appears to be an elevated conversion of adrenal androgens to estrogens
during the daytime when testosterone secretion is low.5,12 In the early stages of puberty,
testosterone secretion occurs primarily at night and with pubertal progression, circulating
gonadotropins and testosterone levels begin to rise during the day. Estrogens, which are
primarily from adrenal androgens, in contrast, start to rise throughout the 24-hour daytime
period in early adolescence. In contrast, adrenal androgens may suppress breast formation
during the daytime in some boys. Boys with pubertal gynecomastia show decreased adrenal
androgen-to-estrogen ratio in the afternoon compared with unaffected boys.13 Either de-
creased adrenal production of androgens or increased aromatization causes this transient
pubertalgynecomastia.Increasedaromataseactivityhasbeenreportedintheskinfibroblasts
of boys affected with gynecomastia, whereas it is not seen in unaffected boys.14
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Figure 4. Macrogynecomastia with female-like breast size and
shape.
Boys showing pubertal gynecomastia usually have breast tissue measuring less than
4cm.Signsofdevelopmentofmalecharacteristicsgenerallyprecedethegynecomastiaand
the adolescent is usually Tanner stages II to III.5 In most cases, the condition resolves in
1 to 3 years. In 75% of boys, the condition disappears in 2 years, and 90% resolve within
3 years. Persistent gynecomastia is seen in less than 5% of affected boys. However, the term
“macrogynecomastia”hasbeenusedtodescribemaleswithglandulartissueexceeding5cm
indiameterandthebreastsresemblingfemalebreastsTannerstageIVwithsecondarymound
formation (Fig 4). This condition rarely regresses spontaneously. Obese individuals may
achieveadecreaseinglandulartissueoritsprominencebyreducingtheirweight.15 Recently,
prepubertal gynecomastia, which is a rare condition and often pathologic, was found to be
associated with lavender and tree tea oils.16 The 2 oils were found to have estrogenic and
antiandrogenicactivities.Theconditionresolvedsoonaftertheboysdiscontinuedthetopical
application. Another recent report of prepubertal gynecomastia came from Germany where
a large family was studied showing dominant transmission of prepubertal gynecomastia
over 3 generations. 17 It was found that a repeat polymorphism of the P450 aromatase gene
cosegregated with the disease phenotype. Excess serum and normal estradiol levels were
present, causing prepubertal gynecomastia and hypogonadism in the boys and the men.
Gynecomastia in adults is frequently multifactorial, resulting from decreased testos-
terone production in the aging testes, increased aromatization of androgens to estrogens
as the body fat increases, and often medications that are more likely taken by older indi-
viduals (Table 3).3,11 Medicines implicated in causing gynecomastia include estrogens or
drugs with estrogen-like activity (Fig 5); antiandrogens or inhibitors of androgen synthesis;
and drugs acting by unknown mechanisms, such as psychoactive drugs, cytotoxic agents,
cardiovascular agents, antiulcer medications, antibiotics, and antiviral therapeutics.
Most patients presenting to a physician for the evaluation of gynecomastia have either
an idiopathic condition or persistent pubertal gynecomastia (Table 2).3 Although physio-
logic gynecomastia is more common than pathologic causes, these other etiologies cannot
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Table 3. Medications implicated in gynecomastia3,5,11
Hormones
Estrogens and estrogen agonists
Androgens and anabolic steroids
Human chorionic gonadotropin
Androgen antagonists
Ketoconazole
Flutamide
Metronidazole
Finasteride
Spironolactone
Etomidate
Antiulcer drugs
Cimetidine
Omeprazole
Ranitidine
Cytotoxic agents
Bisulfar
Vincristine
Nitrosoureas
Procarbazine
Cisplatin
Methotrexate
Cyclophosphamide
Chlorambucil
Psychoactive drugs
Tricyclic antidepressants
Phenothiazines
Diazepam
Cardiovascular agents
Amiodarone
Angiotensin-converting enzyme inhibitors
Calcium channel blockers
Digitoxin
Methyldopa
Antituberculotic agents
Ethionamide
Thiacetazone
Isoniazid
Antiviral therapeutics
Protease inhibiters
Miscellaneous
Marijuana
Heroine
Methadone
Alcohol
Amphetamines
Phenytoin
Penicillamine
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Figure 5. Gynecomastia in an athlete who had taken anabolic
steroids.
Figure 6. Gynecomastia in a patient with chronic liver disease.
be overlooked. Conditions causing hypogonadism and decreased androgen production
and/or action include Klinefelter syndrome, Kallmann syndrome, Reifenstein syndrome,
congenital anorchia, testicular trauma or torsion, viral orichitis, pituitary tumors, malig-
nancies increasing human chorionic gonadotropins (hCGs), renal and liver failure (Fig 6),
hyperthyroidism, malnutrition, androgen insensitivity and 5-α-reductase deficiency, and
other forms of congenital adrenal hyperplasia.3,11 Alcohol causes increased testosterone
clearance from the circulation through enhanced hepatic A-ring reductase activity.6 Also,
several medications such as spironolactone and ketoconazole inhibit testosterone synthesis.
The increased production or action of estrogens can occur peripherally or at the tes-
ticular level.3,11 Testicular tumors producing estrogen or the ectopic production of hCG
such as in the lung and the kidneys and gastrointestinal germ cell tumors can account for
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Figure 7. Left-side breast cancer presenting in a male with asym-
metric breasts.
increased estrogens. In addition, peripheral conversion secondary to increased substrate or
increasedactivityofthearomataseenzymecanleadtoexcessiveestrogens.Increasedarom-
atization occurs during aging, reflecting the relative increase in body fat. Excess estrogens
alsocanoccurinmalnutrition,hyperthyroidism,adrenaltumors,andchronicliverandrenal
diseases. Hyperestrogenic states can decrease androgen secretion by suppressing pituitary
luteinizing hormone, which subsequently suppresses testicular testosterone secretion. High
estrogenlevelsalsoinhibitcytochromeP450c17enzymesinthetestes,whicharenecessary
for testosterone synthesis. The patient’s medication, alcohol use, drug use, smoking habit,
and food history are critical. Other conditions to consider in the differential diagnosis of
breast enlargement, especially unilateral, include dermoid cyst, neurofibroma, lymphan-
gioma, hematoma, lipoma, breast cancer and metastases from neuroblastoma, lymphocytic
leukemia, lymphoma, and rhabdomyosarcoma. Testicular tumors including Sertoli tumors,
Leydig cell tumors, and germ cell tumors can also lead to gynecomastia. Although ac-
counting for less than 1% of male cancers, an accurate diagnosis is critical to determine
breast cancer. It usually presents as a unilateral, eccentric mass that is frequently firm or
attached to underlying tissue (Fig 7). There may also be nipple crusting or discharge and
lymphadenopathy in the axillae.5
Patients frequently present to the surgeon before being evaluated by an endocri-
nologist. What evaluation is necessary to distinguish pathologic from physiologic con-
ditions? It is important to obtain a medication history, a detailed family history, and a
complete medical history to identify cirrhosis, renal failure, hyperthyroidism, other hor-
monal abnormalities, malnutrition, and chest wall trauma. Male adolescents with breast
tissuelessthan4cmindiametergenerallyneedonlyreassuranceandfollow-up.Otherwise,
laboratory tests should include renal, hepatic, and thyroid function studies if indicated
by history or physical examination (Table 4). Boys who appear to have hypogonadism,
macrogynecomastia, or precocious puberty should undergo determinations of luteiniz-
ing hormone, follicle-stimulating hormone, estradiol, dehydroepiandrosterone sulfate, and
hCG. If galactorrhea is present, a prolactin level should be obtained. If any of these tests
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Table 4. Laboratory proﬁle for gynecomastia∗
Complete metabolic profile
β-Human chorionic gonadotropin
Dehydroepiandrosterone sulfate
Luteinizing hormone/follicle-stimulating hormone
Testosterone
Estradiol
Prolactin
Free thyroxine
Thyrotropin
∗Any abnormalities in this profile warrants an endocrinology consult preoperatively.
are abnormal, an endocrinologist should be consulted. If an individual has hard lymph
nodes, dimpling of the skin, and/or breast discharge or bleeding, a malignancy must be
considered. When considering breast cancer, both fine-needle biopsy and mammogram are
indicated.
MEDICAL TREATMENT
The physician should treat the specific condition causing gynecomastia, if one is identified.
Medications that cause gynecomastia should be discontinued. Softening of the glandular
tissue along with decreased tenderness will usually occur by 1 month. However, if breast
development has been present for more than 1 year, it rarely regresses substantially because
offibrosis.Hypogonadismofvariouscausescanbetreatedwithtestosterone,andregression
of gynecomastia should occur if the condition is short term.
Although medical therapy with estrogen antagonists has not been approved for the
treatment of gynecomastia, various researchers have shown different levels of effectiveness
for the regression of both the pain and size of the breast tissue. A retrospective analysis
comparing danazol with tamoxifen was done on 43 patients with idiopathic gynecomastia,
ranging in age from 13 to 82 years (mean = 39.5 years).18 The median size of the breast
tissue was 3 cm and the median duration of gynecomastia was 3 months. Of the 23 patients
who were treated with tamoxifen, complete resolution occurred in 18 (78.2%), whereas
8 of the 20 (40%) who were treated with danazol had complete resolution. A decrease
in pain occurred in 82% of the patients in the tamoxifen group and 75% in the danazol
group. However, 5 patients in the tamoxifen cohort developed recurrences of the breast
mass. There was progressive enlargement in 1 patient in each of the groups undergoing
medical treatment. No adverse effects were seen except for 1 male developing calf muscle
pain, which was shown not to be due to thrombosis.
A prospective study on the use of tamoxifen in physiologic gynecomastia was con-
ducted in 36 men who were classified as having either lump or fatty gynecomastia.19 Lump
gynecomastia was defined as a single palpable solid lesion in the retroareolar region and
was observed in 20 men. Sixteen men had fatty gynecomastia, referring to those presenting
with breast enlargement and no palpable solid lump. The patients ranged in age from 18 to
64 years (mean = 31 years), and the mean duration of gynecomastia was 4 months. Pain
and tenderness were characterized in 25 cases. The patients took tamoxifen for a mean of
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12 weeks (duration = 4–24 weeks). Resolution of the mass occurred in 83.3% of the total
patients, 100% in the lump group and 62.5% in the fatty group. Tenderness decreased in
84% of the total patients, 100% in the lump group and 69% in the fatty group. There was
only 1 recurrence after 7 months. There were no major adverse effects except for a deep
vein thrombosis in a 23-year-old man who sustained major lower limb trauma.
Aretrospectivechartreviewcompared38patientswithpersistentpubertalgynecomas-
tiaassignedtoeithertamoxifenorraloxifenetreatmentgroup.20 Themeanagewas14years,
and the mean duration of gynecomastia was 28.3 months. Tamoxifen is an antiestrogen that
has estrogenic effects in all tissues other than the breast. Raloxifene is a nonsteroidal antie-
strogen that shows estrogenic effects for skeletal and lipid tissues and antiestrogenic effects
for the breasts and the uterus. The mean diameter of breast nodules decreased by 2.1 cm
after tamoxifen treatment and 2.5 cm after raloxifene treatment. Improvement was noted
in 86% of the tamoxifen-treated group and 91% in the raloxifene-treated group. No ad-
verse effects were seen in either group. Thus, in spite of the relatively long duration of
gynecomastia prior to treatment, a high percentage of patients responded to both treatment
modalities. However, because there was no follow-up in untreated patients, the final as-
sessment is murky regarding treatment versus observation alone. In addition, although no
treated patients complained of a recurrence, 40% went for surgery because the medical
treatment did not completely solve the problem.
Anastrozole, another nonapproved treatment for gynecomastia, was evaluated in
a randomized, double-blinded, placebo-controlled study of 80 male adolescents over a
3-monthperiod.21 Anastrozoleisapotentaromataseinhibitorthatdecreasesestrogenlevels
andincreasestestosteroneconcentration.Aresponsewasdefinedas50%ormorereduction
inthecalculatedvolumeofbothbreastsbyusingultrasonography.Intheanastrozolegroup,
there was a 38.5% response versus a 31.4% response in the placebo group. This was not
significant. Similarly, a randomized placebo-controlled study comparing tamoxifen with
anastrozole was evaluated for the prevention of bicalutamide-induced gynecomastia in 93
men with prostate cancer.22,23 Men receiving tamoxifen had a significantly reduced risk of
gynecomastia compared with the anastrozole-treated group in which the risk was similar
to the placebo-treated group. These studies suggest that selective estrogen antagonists may
be the pharmacologic treatment of choice for most patients with gynecomastia.
CONCLUSIONS
Gynecomastia is usually a physiologic condition that may regress over time. The etiology is
often determined as a result of both thorough history and physical examination. However,
an atypical presentation can signify a pathologic state and the surgeon should be aware
of associated problems. If the gynecomastia involves breast tissue of 5 cm or more or if
there is an atypical presentation, a hormonal and sometimes radiologic workup should be
performed. Suspicious breast lesions should be biopsied. Hormonal studies are frequently
difficult to interpret and are based on age and Tanner staging in the adolescents and chil-
dren. When there is a screening laboratory abnormality or if the etiology is in doubt, an
endocrinologist should be consulted. Medical treatments of gynecomastia are currently be-
ing studied, and antiestrogens may become the pharmacologic treatment of choice within
certain presentations and conditions.
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